Skip to main content

Advertisement

Table 1 Patient characteristics

From: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

  Overall Albumin ≥ 4.0 Albumin < 4.0 P value
Number of patients 56 36 20  
Age (year)     0.6563
Median (range) 55 (23–70) 52 (23–70) 56 (28–68)  
ECOG performance status score – no. (%) 0.0877
0 -1 48 (86) 33 15  
2- 8 (14) 3 5  
Histological diagnosis – no. (%)     0.2583
Serous cystadenocarcinoma 37 (66) 25 12  
Endometrioid adenocarcinoma 6 (11) 5 1  
Clear cell adenocarcinoma 5 (8.9) 2 3  
Others 4 (7.1) 3 1  
Unknown 4 (7.1) 1 3  
Site of metastasis – no. (%)     
Peritoneum 29 (52) 20 9 0.1413
Liver 11 (20) 7 4 0.5185
Ascites 21 (38) 13 8 0.4371
Peptide     0.1694
WT1 46 (82) 31 15  
MUC1 39 (70) 27 12  
CA125 16 (29) 7 9  
Number of DC vaccine administration
Median (range) 7 (5–20) 7 (5–18) 7 (5–20) 0.6867